Antipsychotics and risk of natural death in patients with schizophrenia

References

• Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193. doi:10.1038/nature0955221068826
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46(6):729–739.10494440
   PubMed Web of Science ®Google Scholar
• Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6(1):78–85. doi:10.1016/j.nurt.2008.10.02019110200
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet (London, England). 2009;374(9690):620–627. doi:10.1016/S0140-6736(09)60742-X
   PubMed Web of Science ®Google Scholar
• Allebeck P, Rodvall Y, Wistedt B. Incidence of rheumatoid arthritis among patients with schizophrenia, affective psychosis and neurosis. Acta Psychiatr Scand. 1985;71(6):615–619.4024977
   PubMed Web of Science ®Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502–508.9519087
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–1181. doi:10.1001/jamapsychiatry.2015.173726509694
   PubMed Web of Science ®Google Scholar
• Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull. 1996;22(3):413–430. doi:10.1093/schbul/22.3.4138873293
   PubMed Web of Science ®Google Scholar
• Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2006;15(12):873–879. doi:10.1002/pds.132517058327
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–217.11040880
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Syst Rev. 2012;5:Cd008016.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (London, England). 2012;379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-6
   PubMed Web of Science ®Google Scholar
• Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113(1):1–11. doi:10.1016/j.schres.2009.05.01819524406
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600–606. doi:10.1176/appi.ajp.2015.1505061826651392
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. doi:10.1176/appi.ajp.2011.1008122421362741
   PubMed Web of Science ®Google Scholar
• Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–663. doi:10.1093/schbul/sbu16425422511
   PubMed Web of Science ®Google Scholar
• Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103–108. doi:10.4088/JCP.08m04818yel19895781
   PubMed Web of Science ®Google Scholar
• Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a swedish national cohort study. Am J Psychiatry. 2013;170(3):324–333. doi:10.1176/appi.ajp.2012.1205059923318474
   PubMed Web of Science ®Google Scholar
• Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2013;39(5):1159–1168. doi:10.1093/schbul/sbs09723112292
   PubMed Web of Science ®Google Scholar
• Mace S, Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther Adv Psychopharmacol. 2015;5(1):4–12. doi:10.1177/204512531455805425653825
   PubMed Web of Science ®Google Scholar
• Patel MX, Bishara D, Jayakumar S, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24(4):499–509. doi:10.1016/j.euroneuro.2014.01.01424491953
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–457. doi:10.1093/schbul/sbn01818417466
   PubMed Web of Science ®Google Scholar
• Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130–136. doi:10.1176/appi.ajp.162.1.13015625211
   PubMed Web of Science ®Google Scholar
• Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702–708. doi:10.1176/appi.ajp.2011.1006090821536693
   PubMed Web of Science ®Google Scholar
• Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700–706. doi:10.1176/appi.ajp.161.4.70015056517
   PubMed Web of Science ®Google Scholar
• Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res. 2002;57(2–3):147–156.12223245
   PubMed Web of Science ®Google Scholar
• Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res. 2003;117(2):127–135.12606015
   PubMed Web of Science ®Google Scholar
• Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:647476. doi:10.1155/2013/64747624416588
   PubMedGoogle Scholar
• Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122–127. doi:10.1192/bjp.188.2.12216449697
   PubMed Web of Science ®Google Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325–329.9926037
   PubMed Web of Science ®Google Scholar
• Hollis J, Touyz S, Grayson D, Forrester L. Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Aust N Z J Psychiatry. 2006;40(11–12):981–986. doi:10.1080/j.1440-1614.2006.01920.x17054566
   PubMed Web of Science ®Google Scholar
• Bralet MC, Yon V, Loas G, Noisette C. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients]. L’Encephale. 2000;26(6):32–41.
   Google Scholar
• Suzuki T, Uchida H, Tanaka KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004;7(2):133–142. doi:10.1017/S146114570300401214741059
   PubMed Web of Science ®Google Scholar
• Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res. 2014;152(1):246–254. doi:10.1016/j.schres.2013.10.03424275583
   PubMed Web of Science ®Google Scholar
• Ungvari GS, Pang AH, Chiu HF, Wong CK, Lum FC. Psychotropic drug prescription in rehabilitation. A survey in Hong Kong. Soc Psychiatry Psychiatr Epidemiol. 1996;31(5):288–291.8909119
   PubMed Web of Science ®Google Scholar
• Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004;58(1):61–67.14678459
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131. doi:10.1001/archpsyc.64.10.112317909124
   PubMed Web of Science ®Google Scholar
• Rigby JC, Oswald AG. An evaluation of the performing and recording of physical examinations by psychiatric trainees. Br J Psychiatry. 1987;150:533–535.3664136
   PubMed Web of Science ®Google Scholar
• Gournay K. Setting clinical standards for care in schizophrenia. Nurs Times. 1996;92(7):36–37.
   PubMedGoogle Scholar
• Yu Y, Tang BW, Liu ZW, Chen YM, Zhang XY, Xiao S. Who cares for the schizophrenia individuals in rural China – a profile of primary family caregivers. Compr Psychiatry. 2018;84:47–53. doi:10.1016/j.comppsych.2018.04.00229684660
   PubMed Web of Science ®Google Scholar